Clinical Trials on Severe Influenza

Total 6050 results

National Institute of Allergy and Infectious Diseases...
University of Oxford; Wellcome Trust; World Health Organization

Completed

High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza

Influenza | Avian Influenza | Severe Influenza

Singapore, Thailand, Vietnam
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Early Oseltamivir Carboxylate Low Plasma Concentration in Patients Admitted to Intensive Care for Severe Influenza (OPTIFLU)

Severe Influenza

France
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Qingdao Municipal Hospital; Beijing Luhe Hospital; Cangzhou People's Hospital; First... and other collaborators

Unknown

Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

Severe Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

Nontypeable H. Influenzae in Healthy Adults

Haemophilus Influenzae (NTHI)

United States
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
Centers for Disease Control and Prevention
National Institute of Allergy and Infectious Diseases (NIAID); Alaska Native... and other collaborators

Completed

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

Haemophilus Influenzae Type B | Carrier State

United States
Centers for Disease Control and Prevention
Kenya Medical Research Institute; MCM Vaccines B.V.; Kenya Ministry of Health

Unknown

Seasonal Influenza Vaccine Effectiveness Study in Kenya

Influenza | Severe Acute Respiratory Illness | Influenza Like Illness

Kenya
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Clinical Study of MT-2301

Haemophilus Influenza Type b

Japan
Sanofi Pasteur, a Sanofi Company
United States Department of Defense

Completed

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Novartis Vaccines

Completed

Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children

Haemophilus Influenzae Type B Infection

Korea, Republic of
Johns Hopkins Bloomberg School of Public Health
Merck Sharp & Dohme LLC

Completed

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

Haemophilus Influenzae Type B Infection

United States
Beijing Minhai Biotechnology Co., Ltd

Unknown

Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried

Haemophilus Influenzae Type b Infections

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
Hospices Civils de Lyon

Completed

Severe Influenza Cohort (ANTIGRIPPE)

Influenza | Severe Respiratory Infection

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America

Dengue | Dengue Hemorrhagic Fever

Brazil
Mahidol University

Completed

Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (PKIDEN)

Dengue Hemorrhagic Fever

Thailand
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

Dengue Hemorrhagic Fever

United States
Lieselot Houspie

Unknown

Nasal Specimen Collection Study in Patients With ILI and/or ARI in an Outpatient Setting

Influenza-like Illness | Influenzal Acute Respiratory Infection

Belgium
Institut National de la Santé Et de la Recherche...

Completed

Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults (FLUVAC EV-03)

Severe Acute Respiratory Infection

France
Sanofi Pasteur, a Sanofi Company

Completed

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Yellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Haemophilus Influenzae Type b

China
Novartis Vaccines

Completed

Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Haemophilus Influenzae Type b

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Indonesia, Philippines, Malaysia, Thailand, Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Dengue Fever | Dengue Haemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever | Dengue Hemorrhagic Fever

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Shock Syndrome

Puerto Rico
Sanofi

Completed

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
LG Life Sciences

Completed

Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age

Infectious Disease by Haemophilus Influenzae Type b

Korea, Republic of
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Recruiting

Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome

Dengue Fever

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras
St. Petersburg Research Institute of Vaccines and...

Completed

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Vaccines | Haemophilus Influenzae Infection

Russian Federation

Clinical Trials on Severe Influenza

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations